What's Happening?
Biogen and Eisai are facing a three-month delay from the FDA regarding their application to use a subcutaneous formulation of their Alzheimer's therapy, Leqembi, for treatment initiation. The FDA has requested additional information, classifying the submission
as a major amendment, which has pushed the decision date from May 24 to August 24. Leqembi, initially approved in January 2023, is currently administered intravenously. The new subcutaneous version, Leqembi Iqlik, was approved for maintenance treatments in September 2025, allowing for at-home administration. Biogen and Eisai aim to use this formulation from the start of treatment, eliminating the need for intravenous infusions. Analysts suggest the delay will have limited impact on Biogen, as reimbursements for the drug are not expected until 2027.
Why It's Important?
The delay in FDA approval for the subcutaneous version of Leqembi could affect Biogen and Eisai's competitive positioning in the Alzheimer's treatment market. The subcutaneous formulation offers a more convenient administration method, potentially increasing patient adherence and expanding market reach. This development is crucial as it could influence the companies' ability to compete with Eli Lilly's Kisunla, which offers a once-monthly infusion. The decision also impacts the broader pharmaceutical industry, as it highlights the regulatory challenges and timelines associated with bringing new drug formulations to market. The outcome of this review could set precedents for future drug approvals, particularly in the field of Alzheimer's treatments.
What's Next?
Biogen and Eisai are expected to provide the additional information requested by the FDA to support their application for the subcutaneous formulation of Leqembi. The companies anticipate a decision by August 24, which will determine whether they can proceed with offering the subcutaneous version as an initial treatment option. If approved, this could significantly enhance the convenience and accessibility of Alzheimer's treatment, potentially increasing market adoption. The pharmaceutical industry will be closely monitoring this decision, as it may influence future regulatory strategies and competitive dynamics in the Alzheimer's treatment space.
